ArticleStem cell research & therapy2025
Mesenchymal stem cell extracellular vesicles ameliorate radiation-caused dry mouth via modulating immune balance and cell metabolism.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Radiation therapy of head and neck cancers frequently leads to irreversible dry mouth that severely compromises the quality of life and is difficult to remedy. Mesenchymal stem cells (MSCs) could ameliorate this adverse effect, but their application is limited by high variations of conventional tissue-derived MSCs and many practical challenges of cell therapies. This study investigated the potential of extracellular vesicles (EVs) from standardized MSCs derived from iPS cells (iMSCs) in ameliorating radiation-caused dry mouth. In a mouse model, locally injected young but not aging iMSC-EVs after radiation preserved saliva secretion and acinar structures. Mechanistically, young iMSC-EVs reversed the acute inhibition of physiological inflammation and chronic increase of pathogenic inflammation in radiated salivary glands, which is related to the preservation of tissue-resident macrophages and polarization of infiltrated macrophages. At both acute and chronic phase after radiation, iMSC-EVs enhanced mitochondria-related cell metabolism pathways such as Oxidative Phosphorylation that modulate cell survival and macrophage polarization. OXPHOS-promoting protein eIF5A and spermidine required for functional eIF5A hypusination are much richer in effective young iMSC-EVs compared with inert aging EVs. Moreover, young iMSC-EV treatment increased hypusinated eIF5A in radiated salivary glands, especially in macrophages. These findings together indicated that iMSC-EVs are a promising cell-free product to restore salivary gland function impaired by radiation, which is mediated by maintaining immune balance and mitochondria-related cell metabolism at both acute and chronic phases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.